Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

Part of paid clinical trials in Phoenix, Arizona.

Sponsor: Zura Bio Inc
Study ID: NCT06993610
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex: ALL
Age: 18 Years - 70 Years
Healthy Volunteers: Not accepted

Interventions

Tibulizumab Dose A — BIOLOGICAL
Anti BAFF/IL-17 antibody. ZB-106
Tibulizumab Dose B — BIOLOGICAL
Anti BAFF/IL-17 antibody. ZB-106
Placebo — OTHER
ZB-106 Placebo

Study Details

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

Key Dates

Start date: May 16, 2025
Status verified: Feb 2026
Primary completion: Nov 30, 2026
Completion: Apr 30, 2027

Study Design

Enrollment: 225 participants (estimated)
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: Tibulizumab Dose A
Subcutaneous injection
Experimental: Tibulizumab Dose B
Subcutaneous injection
Placebo Comparator: Placebo
Subcutaneous injection

Primary Outcome Measure

[Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeks [ Time Frame: Week 16 ]

Central Contacts

Chief Medical Officer
702-825-9872
[email protected]

Locations (31)

Facility	City	State	ZIP	Site coordinators
Medical Dermatology Specialists (Phoenix)	Phoenix	Arizona	85006	Principal Investigator [email protected] 702-825-9872
First OC Dermatology Research, Inc.	Irvine	California	92614	Principal Investigator [email protected] 702-825-9872
Wallace Medical Group, Inc.	Los Angeles	California	90056	Principal Investigator [email protected] 702-825-9872
Northridge Clinical Trials	Northridge	California	91325	Principal Investigator [email protected] 702-825-9872
NorCal Clinical Research	Rocklin	California	95765	Principal Investigator [email protected] 702-825-9872
Florida Academic Dermatology Center	Coral Gables	Florida	33134	Principal Investigator [email protected] 702-825-9872
Georgia Skin & Cancer Clinic	Savannah	Georgia	31419	Principal Investigator [email protected] 702-825-9872
Indiana University School of Medicine	Indianapolis	Indiana	46202	Principal Investigator [email protected] 702-825-9872
The Indiana Clinical Trials Center	Plainfield	Indiana	46168	Principal Investigator [email protected] 702-825-9872
Equity Medical LLC (Kentucky)	Bowling Green	Kentucky	42104	Principal Investigator [email protected] 702-825-9872
DS Research of Kentucky, LLC	Louisville	Kentucky	40241	Principal Investigator [email protected] 702-825-9872
DelRicht LLC	Baton Rouge	Louisiana	70809	Principal Investigator [email protected] 702-825-9872
Clinical Trials Management, LLC	Metairie	Louisiana	70006	Principal Investigator [email protected] 702-825-9872
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	Principal Investigator [email protected] 702-825-9872
MediSearch Clinical Trials	Saint Joseph	Missouri	64506	Principal Investigator [email protected] 702-825-9872
Skin Cancer and Dermatology Institute	Reno	Nevada	89509	Principal Investigator [email protected] 702-825-9872
Equity Medical	New York	New York	10023	Principal Investigator [email protected] 702-825-9872
OptiSkin Medical	New York	New York	10128	Principal Investigator [email protected] 702-825-9872
Optima Research	Boardman	Ohio	44512	Principal Investigator [email protected] 702-825-9872
ClinOhio Research Services	Columbus	Ohio	43213	Principal Investigator [email protected] 702-825-9872
Apex Clinical Research Center	Mayfield Heights	Ohio	44124	Principal Investigator [email protected] 702-825-9872
Best Skin Research LLC	Camp Hill	Pennsylvania	17011	Principal Investigator [email protected] 702-825-9872
Palmetto Clinical Trial Services	Anderson	South Carolina	29625	Principal Investigator [email protected] 702-825-9872
DelRicht Research	Mt. Pleasant	South Carolina	29464	Principal Investigator [email protected] 702-825-9872
International Clinical Research - Tennessee LLC	Murfreesboro	Tennessee	37130	Principal Investigator [email protected] 702-825-9872
BRCR Global Texas	Katy	Texas	77450	Principal Investigator [email protected] 702-825-9872
DelRicht Research	Prosper	Texas	75078	Principal Investigator [email protected] 702-825-9872
Progressive Clinical Research	San Antonio	Texas	78213	Principal Investigator [email protected] 702-825-9872
Frontier Dermatology	Mill Creek	Washington	98012	Principal Investigator [email protected] 702-825-9872
University of Washington Medical Center	Seattle	Washington	98164	Principal Investigator [email protected] 702-825-9872
Dermatology Specialists of Spokane	Spokane	Washington	99202	Principal Investigator [email protected] 702-825-9872

Find similar trials in Phoenix, AZ

By research site

Medical Dermatology Specialists (Phoenix)· Phoenix, AZ First OC Dermatology Research, Inc.· Irvine, CA Wallace Medical Group, Inc.· Los Angeles, CA Northridge Clinical Trials· Northridge, CA NorCal Clinical Research· Rocklin, CA Florida Academic Dermatology Center· Coral Gables, FL

Related Studies

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
PHASE3 · Recruiting · Incyte Corporation · Birmingham, Alabama
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Recruiting · Sonoma Biotherapeutics, Inc. · San Francisco, California
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
PHASE1 · Recruiting · Wynn Medical Center · Rosemead, California
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
PHASE2 · Recruiting · Incyte Corporation · Birmingham, Alabama